Stellar Pharmaceuticals Announces the Successful Completion of a Quality Management System Upgrade.LONDON -- Stellar Pharmaceuticals Inc. ("Stellar") (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:SLX SLX Student Loan Xpress SLX Smartlet Xml SLX Secure Links SLX Super Luxe )(OTCBB OTCBB See OTC Bulletin Board (OTCBB). :SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that it has successfully completed a Quality Management System upgrade conforming to the new requirements of the ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 13485:2003 standard. Since August 2003 Stellar has been compliant to the ISO 13485:1996 Standard and completing this upgrade is important for Stellar to remain compliant with the new Canadian Medical Device Regulations. Stellar has also met and satisfied the requirements of a Quality Management System assessment (on-site quality audit), a prerequisite for the application of the NeoVisc CE mark certification. Peter Riehl, Stellar's President and Chief Executive Officer, stated, "This is an important first step in obtaining the CE mark for the distribution of NeoVisc in the European market. The Company is committed to obtaining the CE certification for its NeoVisc product and is presently awaiting approval of the technical file submission from the European regulatory authorities." About Stellar Pharmaceuticals Inc. Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc(R), for the treatment of osteoarthritis; and Uracyst(R) and the Uracyst(R) Test Kit, its patented technology for the diagnosis and treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Stellar also has an in-licensing agreement for NMP22(R) BladderChek(R), a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed from time to time in the Company's filings. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept resp onsibility for the adequacy or accuracy of this release. Stellar Pharmaceuticals Inc. (TSX VENTURE:SLX) (OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. :SLXCF) |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion